FORTY SEVEN INC. news, videos and press releases
For more news please use our advanced search feature.
FORTY SEVEN INC. - More news...
FORTY SEVEN INC. - More news...
- Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
- Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia
- Forty Seven to Present at Upcoming Investor Conferences in March
- Forty Seven to Present at Upcoming Investor Conferences in February
- Forty Seven Announces 2020 Strategic Priorities and Expected Milestones
- Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares
- Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock
- Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
- Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
- Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights
- Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting
- Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
- Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference
- Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference
- Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights
- Forty Seven Inc. to Report Second Quarter 2019 Financial Results on Tuesday, August 13, 2019
- Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome
- Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth Conference
- Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares
- Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock
- Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
- Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
- Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
- Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
- Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
- Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
- Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
